



CrossMark

**“Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice.” Brigitte Benard, Valérie Bastien, Benjamin Vinet, Roger Yang, Maja Krajinovic and Francine M. Ducharme. *Eur Respir J* 2017; 50: 1700148.**

This article from the August 2017 issue of the *European Respiratory Journal* was published with an error in the abstract stating that the United States Food and Drug Administration (FDA) had issued a black box warning for montelukast. The warning issued by the FDA was not a black box warning. The corrected sentence reads as follows:

“Although montelukast is generally well tolerated, postmarketing studies have reported serious neuropsychiatric adverse drug reactions (ADRs) leading to a United States Food and Drug Administration warning.”

The article has been corrected and republished online.

Copyright ©ERS 2017